Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
Two children with Guillain-Barrè syndrome were successfully treated with high-dose intravenous immunoglobulin (IVIG) and no relapses occurred over a 1 year follow up. No side-effects were observed. These data provide further evidence that IVIG may be safely and effectively employed in children with Guillain-Barrè syndrome.
Notarangelo
L D
LD
Department of Paediatrics, University of Brescia, Italy.
Duse
M
M
Tiberti
S
S
Guarneri
B
B
Brunori
A
A
Negrini
A
A
Ugazio
A G
AG
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D011129:Polyradiculoneuropathy / Q000628:therapy*; D012008:Recurrence
D016756:Immunoglobulins, Intravenous